

CTI - Ischaemic Heart Disease February 2010

Adis Clinical Trials Insight: Ongoing Trials – Status Tracking February 2010

The table below highlights the ongoing trials whose status has changed during February 2010

| Adis CTI Record | Drug(s) | Study Status | Study Phase | Headline | Sponsor |
|-----------------|--|------------------------------|-------------|---|---|
| 1 700037119 | Alendronic-acid | Active, no longer recruiting | II | Alendronic acid: therapeutic use Prevention of coronary artery restenosis In patients with de novo stenotic lesions in native coronary arteries undergoing percutaneous coronary intervention with bare metal stent | BIOrest |
| 2 700018681 | Alendronic-acid | Completed | IV | Alendronic acid: pharmacodynamics Effects on vascular calcification and arterial stiffness In patients with chronic kidney disorders | |
| 3 700038893 | Antiretrovirals Aspirin | Active, no longer recruiting | II | Aspirin + antiretrovirals: pharmacodynamics Assessing effect on cardiovascular risk In patients with HIV infections | |
| 4 700049892 | Aspirin Clopidogrel | Active, no longer recruiting | III | Aspirin +/- clopidogrel: therapeutic use Transient ischaemic attacks, Stroke The POINT trial | |
| 5 700028371 | Atorvastatin Fluvastatin Pitavastatin Pravastatin | Completed | IV | Atorvastatin, fluvastatin, pitavastatin, pravastatin: therapeutic use Atherosclerosis Intensive vs moderate lipid lowering in patients with acute coronary syndromes | |
| 6 700015116 | Bivalirudin Heparin | Completed | IV | Bivalirudin vs heparin: therapeutic use Prevention of cardiovascular disorders In patients undergoing percutaneous coronary interventions | Nycomed Pharma GmbH |
| 7 700040396 | Cardiovascular-therapies | Completed | III | Cardiovascular therapies: therapeutic use Prevention of cardiovascular disorders Fixed-dose combination medication in those at raised risk of cardiovascular disease | |
| 8 700052273 | Ciclosporin Tacrolimus Telaprevir | Active, no longer recruiting | I | Tacrolimus +/- telaprevir, ciclosporin +/- telaprevir: pharmacokinetics Potential pharmacokinetic interactions In volunteers | Tibotec Pharmaceuticals, Vertex Pharmaceuticals |
| 9 700052174 | Cilostazol Probucol | Recruiting | IV | Cilostazol +/- probucol: therapeutic use Atherosclerosis Effect on plaque stabilisation and lesion regression | Otsuka Pharmaceutical |

CTI - Ischaemic Heart Disease February 2010

| Adis CTI Record | Drug(s) | Study Status | Study Phase | Headline | Sponsor |
|-----------------|---------------------------|------------------------------|-------------|---|-------------------------------|
| 10 700032078 | Dalcetrapib | Active, no longer recruiting | III | Dalcetrapib: therapeutic use Acute coronary syndromes In patients receiving standard treatment | Roche |
| 11 700018677 | Epoetin-beta | Completed | II | Epoetin beta: pharmacodynamics Effects on cardiac ischaemic markers After coronary bypass surgery | Roche |
| 12 700029202 | Estradiol Progesterone | Active, no longer recruiting | II | Estradiol + progesterone vs estradiol: pharmacodynamics Effects on myocardial fatty acid metabolism In healthy post-menopausal women | |
| 13 700053686 | Everolimus Paclitaxel | Recruiting | III | Paclitaxel vs everolimus: therapeutic use Prevention of coronary artery restenosis Drug-eluting Xience V stent (Abbott Vascular) vs SeQuent Please balloon (BBraun); an optical coherence tomography evaluation | |
| 14 700041187 | ILS-920 | Completed | I | ILS 920: adverse reactions Various toxicities In volunteers | Wyeth |
| 15 700017688 | Isosorbide-dinitrate | Discontinued | IV | Isosorbide dinitrate: therapeutic use Angina pectoris Intravenous vs sublingual administration In patients with acute coronary syndromes | |
| 16 700021202 | Metoprolol | Recruiting | IV | Metoprolol: therapeutic use Secondary prevention of myocardial infarction In combination with pacemaker in patients with slow heart rates after myocardial infarction: efficacy and quality-of-life analysis | |
| 17 700037769 | Paclitaxel | Completed | III | Paclitaxel: therapeutic use Prevention of coronary artery restenosis In patients undergoing drug eluting stent implantation and percutaneous coronary intervention | Boston Scientific Corporation |
| 18 700028976 | Paclitaxel | Completed | II/III | Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents versus brachytherapy | Boston Scientific Corporation |
| 19 700027758 | Paclitaxel | Completed | II/III | Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents vs bare stents in patients with de novo lesions | Boston Scientific Corporation |

CTI - Ischaemic Heart Disease February 2010

| Adis CTI Record | Drug(s) | Study Status | Study Phase | Headline | Sponsor |
|-----------------|--------------------------------|------------------------------|-------------|---|---------------------------------|
| 20 700035549 | Paclitaxel | Completed | IV | Paclitaxel: therapeutic use Prevention of coronary artery restenosis In patients with multivessel coronary artery disease | Boston Scientific Corporation |
| 21 700035244 | Paclitaxel | Active, no longer recruiting | III | Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents in patients with myocardial ischaemia | Braun Melsungen |
| 22 700046860 | Paclitaxel | Active, no longer recruiting | IV | Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents in patients with with de novo coronary lesions undergoing angioplasty | Sahajanand Medical Technologies |
| 23 700043330 | Paclitaxel | Completed | IV | Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents vs bare stents in patients with type 2 diabetes mellitus | Translumina Labs |
| 24 700000091 | Rosiglitazone Sulfonylureas | Completed | II | Rosiglitazone, sulfonylureas: pharmacodynamics Effects on cardiac ischaemia, blood pressure and associated risk factors In patients with chronic stable angina and type 2 diabetes mellitus | GlaxoSmithKline |
| 25 700051873 | RVX-208 | Recruiting | II | RVX 208: therapeutic use Coronary artery disease In patients with unstable disease: ASSURE-1 IVUS study | Resverlogix Corporation |
| 26 700034849 | RVX-208 | Active, no longer recruiting | II | RVX 208: therapeutic use Atherosclerosis Phase IIb study in patients with stable coronary disease: ASSERT | Resverlogix Corporation |
| 27 700037477 | Sirolimus | Completed | IV | Sirolimus: therapeutic use Prevention of coronary artery restenosis In patients with angina pectoris | Cordis Corporation |
| 28 700025898 | Sirolimus | Completed | IV | Sirolimus: therapeutic use Prevention of coronary artery restenosis Cost effectiveness of drug-eluting vs bare metal stents in patients with diabetes | Cordis Corporation |
| 29 700049560 | SLV-342 | Recruiting | I | SLV 342: adverse reactions Various toxicities In volunteers | Solvay Pharmaceuticals |

CTI - Ischaemic Heart Disease February 2010

| Adis CTI Record | Drug(s) | Study Status | Study Phase | Headline | Sponsor |
|---------------------|-----------------|--------------|-------------|--|--------------------------------|
| 30 700023109 | Thymosin-beta-4 | Completed | I | Thymosin beta 4: adverse reactions Various toxicities Single and multiple dose trial in volunteers | RegeneRx Biopharmaceuticals |
| 31 700035606 | Zotarolimus | Completed | III | Zotarolimus: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents vs bare metal stent in patients with acute myocardial infarction | Medtronic |

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.